Quanterix Overview
- Year Founded
-
2007

- Status
-
Public
- Employees
-
136

- Stock Symbol
-
QTRX

- Investments
-
4
- Share Price
-
$5.60
- (As of Thursday Closing)
Quanterix General Information
Description
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Contact Information
Website
www.quanterix.comCorporate Office
- 900 Middlesex Turnpike
- Building 1
- Billerica, MA 01821
- United States
Corporate Office
- 900 Middlesex Turnpike
- Building 1
- Billerica, MA 01821
- United States
Quanterix Stock Performance
As of 24-Apr-2025, Quanterix’s stock price is $5.60. Its current market cap is $217M with 38.8M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.60 | $5.34 | $4.67 - $19.18 | $217M | 38.8M | 748K | -$1.00 |
Quanterix Financials Summary
As of 31-Dec-2024, Quanterix has a trailing 12-month revenue of $135M.
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 154,482 | 154,482 | 748,954 | 212,428 |
Revenue | 135,436 | 135,436 | 121,139 | 104,952 |
EBITDA | (44,396) | (44,396) | (35,184) | (98,417) |
Net Income | (38,531) | (38,531) | (28,354) | (99,574) |
Total Assets | 406,533 | 406,533 | 428,567 | 433,582 |
Total Debt | 37,371 | 37,371 | 41,464 | 44,104 |
Quanterix Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Quanterix Comparisons
Industry
Financing
Details
Quanterix Competitors (13)
One of Quanterix’s 13 competitors is Siemens Healthineers, a Corporation company based in Forchheim, Germany.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Siemens Healthineers | Corporation | Forchheim, Germany | ||||
Cepheid | Formerly VC-backed | Sunnyvale, CA | ||||
T2 Biosystems | Formerly VC-backed | Lexington, MA | ||||
Chembio Diagnostic | Corporate Backed or Acquired | Medford, NY | ||||
Accelerate Diagnostics | Corporation | Tucson, AZ |
Quanterix Patents
Quanterix Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220205992-A1 | Materials and kits relating to association of reporter species and targeting entities with beads | Inactive | 28-Dec-2020 | ||
US-20220050106-A1 | Methods and kits for detecting sars-coronavirus-2 antigen | Pending | 14-Aug-2020 | ||
US-20210341479-A1 | Quantitative antibody test | Active | 30-Apr-2020 | ||
US-11686730-B2 | Quantitative antibody test | Active | 30-Apr-2020 | ||
EP-4135897-A2 | Methods and systems related to highly sensitive, digital assays by improved delivery of capture objects | Pending | 15-Apr-2020 | G01N33/54386 |
Quanterix Signals
Quanterix Acquisitions (4)
Quanterix’s most recent deal was a Merger/Acquisition with Akoya Biosciences. The deal was made on 10-Jan-2025.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Akoya Biosciences | 10-Jan-2025 | Merger/Acquisition | Other Healthcare Technology Systems | ||
Emission | 08-Jan-2025 | Merger/Acquisition | Other Commercial Products | ||
UmanDiagnostics | 01-Aug-2019 | Merger/Acquisition | Diagnostic Equipment | ||
Aushon BioSystems | 30-Jan-2018 | Merger/Acquisition | Discovery Tools (Healthcare) |
Quanterix ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
25.43 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile

Pharmaceuticals
Industry
of 861
Rank
Percentile

Laboratory Equipment and Services
Subindustry
of 60
Rank
Percentile

Quanterix Affiliates
Subsidiaries (2)
Name | Industry | Location | Year Founded |
---|---|---|---|
Emission | Georgetown, TX | 2020 | |
UmanDiagnostics | Umea, Sweden | 2006 |
Quanterix FAQs
-
When was Quanterix founded?
Quanterix was founded in 2007.
-
Where is Quanterix headquartered?
Quanterix is headquartered in Billerica, MA.
-
What is the size of Quanterix?
Quanterix has 136 total employees.
-
What industry is Quanterix in?
Quanterix’s primary industry is Diagnostic Equipment.
-
Is Quanterix a private or public company?
Quanterix is a Public company.
-
What is Quanterix’s stock symbol?
The ticker symbol for Quanterix is QTRX.
-
What is the current stock price of Quanterix?
As of 24-Apr-2025 the stock price of Quanterix is $5.60.
-
What is the current market cap of Quanterix?
The current market capitalization of Quanterix is $217M.
-
What is Quanterix’s current revenue?
The trailing twelve month revenue for Quanterix is $135M.
-
Who are Quanterix’s competitors?
Siemens Healthineers, Cepheid, T2 Biosystems, Chembio Diagnostic, and Accelerate Diagnostics are some of the 13 competitors of Quanterix.
-
What is Quanterix’s annual earnings per share (EPS)?
Quanterix’s EPS for 12 months was -$1.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »